---
title: "Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286611724.md"
description: "Gilead Sciences Inc. (GILD) shares fell 1.88% to $129.58 on Friday, marking the third consecutive day of losses. The stock is now 17.62% below its 52-week high of $157.29. In comparison, competitors like Johnson & Johnson, Pfizer, and Abbott also experienced declines, but Gilead underperformed relative to them. Trading volume reached 6.6 million, surpassing the 50-day average of 5.9 million."
datetime: "2026-05-15T20:35:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286611724.md)
  - [en](https://longbridge.com/en/news/286611724.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286611724.md)
---

# Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Gilead Sciences Inc. (GILD) shed 1.88% to $129.58 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 1.24% to 7,408.50 and Dow Jones Industrial Average falling 1.07% to 49,526.17.

This was the stock's third consecutive day of losses.

Gilead Sciences Inc. closed 17.62% below its 52-week high of $157.29, which the company achieved on February 11th.

The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) fell 1.77% to $226.71, Pfizer Inc. (PFE) fell 1.63% to $25.33, and Abbott Laboratories (ABT) fell 0.51% to $84.47.

Trading volume (6.6 M) eclipsed its 50-day average volume of 5.9 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 15, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-15-26 1635ET

### Related Stocks

- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)

## Related News & Research

- [ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/286893590.md)
- [Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline](https://longbridge.com/en/news/286673327.md)
- [Gilead Sciences prices $3B multi-tranche senior notes offering](https://longbridge.com/en/news/286518399.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md)